293 related articles for article (PubMed ID: 37760542)
41. Immunotherapy after liver transplantation: Where are we now?
Au KP; Chok KSH
World J Gastrointest Surg; 2021 Oct; 13(10):1267-1278. PubMed ID: 34754394
[TBL] [Abstract][Full Text] [Related]
42. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period.
Chen GH; Wang GB; Huang F; Qin R; Yu XJ; Wu RL; Hou LJ; Ye ZH; Zhang XH; Zhao HC
Transpl Immunol; 2021 Jun; 66():101386. PubMed ID: 33744409
[TBL] [Abstract][Full Text] [Related]
43. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
[TBL] [Abstract][Full Text] [Related]
44. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
45. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
[No Abstract] [Full Text] [Related]
46. Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors.
Moshirfar M; Basharat NF; Seitz TS; Ply BK; Ronquillo YC; Hoopes PC
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233514
[TBL] [Abstract][Full Text] [Related]
47. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation.
Ouranos K; Chatziioannou A; Goulis I; Sinakos E
World J Transplant; 2022 Nov; 12(11):331-346. PubMed ID: 36437845
[TBL] [Abstract][Full Text] [Related]
48. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
Akce M; El-Rayes BF; Wajapeyee N
Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
[TBL] [Abstract][Full Text] [Related]
49. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.
Chen L; Zhang R; Lin Z; Tan Q; Huang Z; Liang B
Front Immunol; 2023; 14():1100079. PubMed ID: 36742293
[TBL] [Abstract][Full Text] [Related]
50. Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study.
Paul S; Zahurak M; Luznik L; Ambinder RF; Fuchs EJ; Bolaños-Meade J; Wagner-Johnston N; Swinnen LJ; Schoch L; Varadhan R; Jones RJ; Gladstone DE
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1679-1688. PubMed ID: 32592857
[TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
[TBL] [Abstract][Full Text] [Related]
52. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
53. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
54. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates.
Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N
Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193
[TBL] [Abstract][Full Text] [Related]
55. Immunotherapy in older patients with hepatocellular carcinoma.
Lyu N; Yi JZ; Zhao M
Eur J Cancer; 2022 Feb; 162():76-98. PubMed ID: 34954439
[TBL] [Abstract][Full Text] [Related]
56. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma.
Lee PC; Chao Y; Chen MH; Lan KH; Lee IC; Hou MC; Huang YH
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863270
[TBL] [Abstract][Full Text] [Related]
57. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
[TBL] [Abstract][Full Text] [Related]
58. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
[TBL] [Abstract][Full Text] [Related]
59. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Machairas N; Tsilimigras DI; Pawlik TM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454923
[TBL] [Abstract][Full Text] [Related]
60. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
Liu TH; Shen YC; Cheng AL
J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
